

Response for Reconside

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: F. Haviv, et al.

Serial No.: 09/718,591

Filed: November 22, 2000

For: PEPTIDES HAVING

ANTIANGIOGENIC ACTIVITY

Examiner: David Lukton

Group Art Unit: 1653

Case No.: 6633.US.O2

Commissioner for Patents 5 P.O. Box 1450 Alexandria, VA 22313-1450 **CERTIFICATE OF MAILING (37 CFR**

1.8 (a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

RECEIVED

JUN 10 2003

TECH CENTER 1600/2900

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: June 2, 2003

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

The following is in response to the Office Action dated May 2, 2003, having a period of response through June 2, 2003. Reconsideration is respectfully requested.

REMARKS

Claims 1-30 are pending in the application. Claims 1-30 are subject to an election/restriction requirement. Applicants respectfully traverse the requirement.

Applicants hereby elect, with traverse, Invention 2: claims 1-25, 27, 29, and 30 drawn to compounds limited to G2. G2 has been defined by the Examiner as "Xaal can be whatever 20 the claims permit, provided that G1 is excluded." G1 has been defined by the Examiner as "Xaa1 is absent, or a hydrogen atom." The claims have been amended in accordance with the restriction requirement.

Applicants elect Example 1 as a species for search purposes. This example is found on pages 32-34 of the specification and is generically recited in claims 1-25 and claim 27 and 25

15

10